| Lung Cancer |
1 |
1 |
| Non-Small Cell Lung Cancer |
0 |
0.81 |
| KRAS |
0 |
0.99 |
| Small Cell Lung Cancer |
0 |
0.56 |
| Cancer |
0 |
0.48 |
| Lung |
0 |
0.42 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.24 |
| Tumor |
0 |
0.18 |
| Europe |
0 |
0.12 |
| Food and Drug Administration (FDA) |
0 |
0.12 |
| Diarrhea |
0 |
0.08 |
| Patient Safety |
0 |
0.08 |
| Adverse Effects |
0 |
0.06 |
| Aminotransferase |
0 |
0.06 |
| Arthralgia |
0 |
0.06 |
| Chemotherapy |
0 |
0.06 |
| Fatigue |
0 |
0.06 |
| Nausea |
0 |
0.06 |
| New York |
0 |
0.06 |
| Platinum |
0 |
0.06 |